Trial Profile
Pharmacokinetics and Safety of BI 695501 in Healthy Subjects: a Randomized, Double-blind, Single Dose, Parallel-arm, Active Comparator Clinical Phase I Study
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Adalimumab (Primary)
- Indications Rheumatoid arthritis
- Focus Pharmacokinetics
- Acronyms VOLTAIRE-PK
- Sponsors Boehringer Ingelheim Pharmaceuticals
- 03 May 2020 Results published in the British Journal of Clinical Pharmacology
- 28 Oct 2015 Results presented at the 2015 American Association of Pharmaceutical Scientists (AAPS) Annual Meeting, according to a Boehringer Ingelheim media release.
- 25 Jun 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.